Clinical Trial Update: Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating whether monosialoganglioside GM1 can prevent neurotoxicity caused by albumin-bound paclitaxel in lung cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Monosialoganglioside GM1 (GM1 monosialoganglioside)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Neurotoxicity | Phase 2 | Status: UNKNOWN